Boryung said Thursday it has launched Dasakin (dasatinib), the first generic version of dasatinib approved in Korea for chronic myeloid leukemia (CML).
Dasakin is a second-generation targeted cancer therapy that inhibits the BCR-ABL fusion protein, a tyrosine kinase associated with cancer cell growth. The drug is mainly used to treat chronic myeloid leukemia, a blood cancer.
Dasakin brand image. (Courtesy of Boryung)
The product is available in five dosage strengths -- 20 mg, 50 mg, 70 mg, 80 mg and 100 mg. Boryung said it is the only company in Korea offering a 70 mg formulation.
The company said the generic product may help reduce treatment costs for patients requiring long-term therapy.
With the launch of Dasakin following its first-generation CML therapy Glima (imatinib), Boryung has expanded its treatment lineup for chronic myeloid leukemia. Dasatinib is commonly used in patients who develop resistance or intolerance to first-generation treatment.
In March, Boryung also signed a licensing agreement with Antengene for the blood cancer drug Xpovio (selinexor).
The company currently markets nine hematologic cancer treatments, including Glima (imatinib), Velkin (bortezomib), Revlikin (lenalidomide), Pomalikin (pomalidomide), Xpovio (selinexor), Devikin (decitabine), Vizadakin (azacitidine) and Bencord (bendamustine).
Seong Baek-min, head of the BD & Marketing Division at Boryung, said the company launched Dasakin to support treatment continuity for leukemia patients.
Kim Ji-hye
댓글
0